Monopar Therapeutics Stock Market Value
| MNPR Stock | USD 22.53 1.83 8.84% |
| Symbol | Monopar |
Monopar Therapeutics Price To Book Ratio
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Monopar Therapeutics. If investors know Monopar will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Monopar Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.98) | Return On Assets (0.53) | Return On Equity (1.02) |
The market value of Monopar Therapeutics is measured differently than its book value, which is the value of Monopar that is recorded on the company's balance sheet. Investors also form their own opinion of Monopar Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Monopar Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Monopar Therapeutics' market value can be influenced by many factors that don't directly affect Monopar Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Monopar Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Monopar Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Monopar Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Monopar Therapeutics 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to Monopar Therapeutics' stock what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of Monopar Therapeutics.
| 06/03/2024 |
| 11/30/2024 |
If you would invest 0.00 in Monopar Therapeutics on June 3, 2024 and sell it all today you would earn a total of 0.00 from holding Monopar Therapeutics or generate 0.0% return on investment in Monopar Therapeutics over 180 days. Monopar Therapeutics is related to or competes with Tff Pharmaceuticals, Eliem Therapeutics, Inhibrx, Enliven Therapeutics, and Molecular Partners. Monopar Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatm... More
Monopar Therapeutics Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure Monopar Therapeutics' stock current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess Monopar Therapeutics upside and downside potential and time the market with a certain degree of confidence.
| Downside Deviation | 11.22 | |||
| Information Ratio | 0.1365 | |||
| Maximum Drawdown | 653.56 | |||
| Value At Risk | (9.50) | |||
| Potential Upside | 15.93 |
Monopar Therapeutics Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for Monopar Therapeutics' investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as Monopar Therapeutics' standard deviation. In reality, there are many statistical measures that can use Monopar Therapeutics historical prices to predict the future Monopar Therapeutics' volatility.| Risk Adjusted Performance | 0.1157 | |||
| Jensen Alpha | 10.98 | |||
| Total Risk Alpha | (2.16) | |||
| Sortino Ratio | 0.9164 | |||
| Treynor Ratio | (2.33) |
Monopar Therapeutics Backtested Returns
Monopar Therapeutics is out of control given 3 months investment horizon. Monopar Therapeutics has Sharpe Ratio of 0.14, which conveys that the firm had a 0.14% return per unit of risk over the last 3 months. We were able to interpolate data for twenty-nine different technical indicators, which can help you to evaluate if expected returns of 10.84% are justified by taking the suggested risk. Use Monopar Therapeutics Downside Deviation of 11.22, risk adjusted performance of 0.1157, and Mean Deviation of 20.43 to evaluate company specific risk that cannot be diversified away. Monopar Therapeutics holds a performance score of 11 on a scale of zero to a hundred. The company secures a Beta (Market Risk) of -4.46, which conveys a somewhat significant risk relative to the market. As returns on the market increase, returns on owning Monopar Therapeutics are expected to decrease by larger amounts. On the other hand, during market turmoil, Monopar Therapeutics is expected to outperform it. Use Monopar Therapeutics value at risk, as well as the relationship between the kurtosis and price action indicator , to analyze future returns on Monopar Therapeutics.
Auto-correlation | -0.75 |
Almost perfect reverse predictability
Monopar Therapeutics has almost perfect reverse predictability. Overlapping area represents the amount of predictability between Monopar Therapeutics time series from 3rd of June 2024 to 1st of September 2024 and 1st of September 2024 to 30th of November 2024. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of Monopar Therapeutics price movement. The serial correlation of -0.75 indicates that around 75.0% of current Monopar Therapeutics price fluctuation can be explain by its past prices.
| Correlation Coefficient | -0.75 | |
| Spearman Rank Test | -0.82 | |
| Residual Average | 0.0 | |
| Price Variance | 52.09 |
Monopar Therapeutics lagged returns against current returns
Autocorrelation, which is Monopar Therapeutics stock's lagged correlation, explains the relationship between observations of its time series of returns over different periods of time. The observations are said to be independent if autocorrelation is zero. Autocorrelation is calculated as a function of mean and variance and can have practical application in predicting Monopar Therapeutics' stock expected returns. We can calculate the autocorrelation of Monopar Therapeutics returns to help us make a trade decision. For example, suppose you find that Monopar Therapeutics has exhibited high autocorrelation historically, and you observe that the stock is moving up for the past few days. In that case, you can expect the price movement to match the lagging time series.
Current and Lagged Values |
| Timeline |
Monopar Therapeutics regressed lagged prices vs. current prices
Serial correlation can be approximated by using the Durbin-Watson (DW) test. The correlation can be either positive or negative. If Monopar Therapeutics stock is displaying a positive serial correlation, investors will expect a positive pattern to continue. However, if Monopar Therapeutics stock is observed to have a negative serial correlation, investors will generally project negative sentiment on having a locked-in long position in Monopar Therapeutics stock over time.
Current vs Lagged Prices |
| Timeline |
Monopar Therapeutics Lagged Returns
When evaluating Monopar Therapeutics' market value, investors can use the concept of autocorrelation to see how much of an impact past prices of Monopar Therapeutics stock have on its future price. Monopar Therapeutics autocorrelation represents the degree of similarity between a given time horizon and a lagged version of the same horizon over the previous time interval. In other words, Monopar Therapeutics autocorrelation shows the relationship between Monopar Therapeutics stock current value and its past values and can show if there is a momentum factor associated with investing in Monopar Therapeutics.
Regressed Prices |
| Timeline |
Pair Trading with Monopar Therapeutics
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Monopar Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Monopar Therapeutics will appreciate offsetting losses from the drop in the long position's value.Moving together with Monopar Stock
| 0.66 | VTRS | Viatris | PairCorr |
| 0.75 | ESPR | Esperion Therapeutics Buyout Trend | PairCorr |
| 0.65 | EWTX | Edgewise Therapeutics | PairCorr |
Moving against Monopar Stock
| 0.89 | TAK | Takeda Pharmaceutical | PairCorr |
| 0.85 | MRK | Merck Company Fiscal Year End 6th of February 2025 | PairCorr |
| 0.84 | RDY | Dr Reddys Laboratories | PairCorr |
| 0.81 | ZTS | Zoetis Inc | PairCorr |
| 0.8 | LLY | Eli Lilly | PairCorr |
The ability to find closely correlated positions to Monopar Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Monopar Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Monopar Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Monopar Therapeutics to buy it.
The correlation of Monopar Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Monopar Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Monopar Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Monopar Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Additional Tools for Monopar Stock Analysis
When running Monopar Therapeutics' price analysis, check to measure Monopar Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Monopar Therapeutics is operating at the current time. Most of Monopar Therapeutics' value examination focuses on studying past and present price action to predict the probability of Monopar Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Monopar Therapeutics' price. Additionally, you may evaluate how the addition of Monopar Therapeutics to your portfolios can decrease your overall portfolio volatility.